European Psychiatry - Volume 33 - March 2016

264 / 812

S260 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348
school-based universal prevention program for enhancing emo-
tional coping abilities with others’ emotions, which was imple-
mented in eight classes during onemonth. The questionnaires were
utilized for assessing implicit positive and negative affect (IPA and
INA), explicit emotional coping abilities to identify, understand, and
regulate others’ emotions, and the adaptive status of children at
school.
Results Hierarchical regression analyses showed that higher IPA
at T1 was associated with higher explicit emotional coping and
motivation for learning at T2. Also, higher INA at T1 was related
to better peer relationship at T2. Moreover, higher IPA and INA at
T1 were concerned with higher scores of classroom climate and
approval at T2.
Conclusion This study suggested that higher IPA leads to higher
explicit emotional coping with others’ emotions. Also, it suggested
that higher implicit affectivity (i.e., both higher IPA and INA) causes
more adaptive status of children at school.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Psychoneuroimmunology
EW417
Oxidative DNA damage is associated
with antidepressant use, not
depression or anxiety disorders
C. Black ∗, M. Bot , P. Scheffer , B. Penninx
1 VU University Medical Center, Psychiatry/GGZ inGeest, Amsterdam,
Netherlands
2 VU University Medical Center, Clinical Chemistry, Amsterdam,
Netherlands
∗ Corresponding author.
Introduction Oxidative stress has been implicated in the patho-
physiology of depression and anxiety disorders and may be
influenced by antidepressant use.
Objectives This study investigated the association of oxidative
stress, measured by plasma levels of F2-isoprostanes and 8-
hydroxy-2 -deoxyguanosine (8-OHdG), reflecting oxidative lipid
and DNA damage respectively, with major depressive disorder
(MDD), generalized anxiety disorder, social phobia, panic disorder,
agoraphobia and antidepressant use in a large cohort.
Methods Data was derived from the Netherlands Study of
Depression and Anxiety including patients with current (n = 1641)
or remitted (n = 610) MDD and/or anxiety disorder(s) (of which
n = 709 antidepressant users) and 633 controls. Diagnoses were
established with the Composite Interview Diagnostic Instru-
ment. Plasma 8-OHdG and F2-isoprostanes were measured using
UHPLC-MS/MS. ANCOVA was performed adjusting for sampling,
sociodemographic, health and lifestyle variables.
Results F2-isoprostanes did not differ between controls and
patients, or by antidepressant use. Patients (current or remit-
ted) using antidepressants had lower 8-OHdG (adjusted mean
38.3 pmol/L) compared to patients (current or remitted) without
antidepressants (44.7 pmol/L) and controls (44.9 pmol/L, P < 0.001;
Cohen’s d 0.26). Findings for 8-OHdGwere similar over all disorders
and all antidepressant types (SSRIs, TCAs, SNRIs; P < 0.001).
Conclusion Contrary to previous findings this large-scale study
didnot find increased oxidative stressmeasured by F2-isoprostanes
or 8-OHdG in MDD or anxiety disorders. 8-OHdG levels were lower
in antidepressant users, which suggests antidepressants may have
antioxidant properties.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW418
Antioxidant uric acid is lower in
current major depression and anxiety
disorders
C. Black ∗ Bot cheffer enninx
1 VU University Medical Center, Psychiatry/GGZ inGeest, Amsterdam,
Netherlands
2 VU University Medical Center, Clinical Chemistry, Amsterdam,
Netherlands
∗ Corresponding author.
Introduction It has been hypothesized that lowered antioxidant
capacity, which leads to increased oxidative stress, may be involved
in the pathophysiology of major depressive disorder (MDD) and
anxiety disorders and might be altered by antidepressant treat-
ment.
Objectives This study investigated the association of plasma uric
acid, the greatest contributor to blood antioxidant capacity, with
MDD, generalized anxiety disorder, social phobia, panic disorder,
agoraphobia and antidepressants in a large cohort.
Methods Data was derived from the Netherlands Study of
Depression and Anxiety including patients with current (n = 1648)
or remitted (n = 609) MDD and/or anxiety disorder(s) (of which
n = 710 antidepressant users) and 618 controls. Diagnoses were
established with the Composite Interview Diagnostic Instrument.
Symptom severity was ascertained in all participants with the
Inventory of Depressive Symptoms and the Beck Anxiety Inventory.
ANCOVA and regression analyses were adjusted for sociodemo-
graphic, health and lifestyle variables.
Results Plasma uric acid was lower in those with current MDD
and/or anxiety disorder(s) (adjusted mean 270 mol/L) compared
to those with remitted disorders (280 mol/L, P < 0.001) or to
controls (281 mol/L, P < 0.001; Cohen’s d 0.14). Within patients
antidepressants were not associated with uric acid levels. Increas-
ing symptom severity was associated with lower uric acid levels
for both depression ( = –0.05, P = 0.001) and anxiety symptoms
( = –0.05, P = 0.004).
Conclusion This large scale study finds that the antioxidant uric
acid is lower in current, but not remitted, MDD or anxiety disorders
and in persons with higher symptom severity, suggesting distur-
bances in redox homeostasis play a role in the pathophysiology of
depression and anxiety disorders.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW419
Interleukin-receptor antagonist
(IL1-RA) with respect to schizophrenia
psychopathology
D. Frydecka ∗ isiak edlaczek awlak-Adamska
1 Wroclaw Medical University, Department of Psychiatry, Wrocław,
Poland
2 Wroclaw Medical University, Department of Genetics, Wrocław,
Poland
3 Wroclaw Medical University, Department and Clinic of Gynaecology
and Obsterics, Wrocław, Poland
4 Institute of Immunology and Experimental Therapy, Polish Academy
of Science, Department of Experimental Therapy, Wrocław, Poland
∗ Corresponding author.